You have access
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab
BEATRIZ WILLS, ANDRÉS F. CARDONA, LEONARDO ROJAS, ALEJANDRO RUIZ-PATIÑO, OSCAR ARRIETA, NOEMÍ REGUART, HERNÁN CARRANZA, CARLOS VARGAS, JORGE OTERO, LUIS CORRALES, CLAUDIO MARTÍN, MAURICIO CUELLO, LUIS EDUARDO PINO, CHRISTIAN ROLFO, RAFAEL ROSELL, ZYANYA LUCIA ZATARAIN-BARRÓN and on behalf of The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)
Anticancer Research November 2017, 37 (11) 6429-6436;